Actively Recruiting
Evaluation of Feasibility and Impact of Remote Care in Patients With Thromboembolic Disease of Low Risk
Led by Centre Hospitalier Eure-Seine · Updated on 2025-09-15
50
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the feasibility and impact of remote care for patients diagnosed with low-risk thromboembolic disease. The study aims to understand how well healthcare professionals, including hospital physicians and primary care doctors, can organize care remotely, and to assess rates of complications, hospitalizations, and treatment compliance over 6 months and 1 year. Participants will follow treatment guidelines based on national recommendations. Participants will receive a 4G tablet for the entire study period to complete questionnaires, access educational information about their medications, participate in remote consultations, and track their treatment adherence. The study focuses on measuring satisfaction with the organization of care by patients and healthcare providers, along with monitoring clinical outcomes related to thromboembolic disease. During the study, participants will be regularly assessed through questionnaires and remote consultations using the tablet. Researchers will evaluate satisfaction levels using three different scales for patients, hospital physicians, and primary care physicians at 6 months and 1 year. They will also monitor complication rates, hospitalizations related to thromboembolic disease, and treatment compliance at these time points. The total duration of participation spans at least one year with ongoing monitoring and data collection.
CONDITIONS
Brief Title
Impact of Remote Care in Patients Diagnosed With Thromboembolic Disease of Low Risk
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients identified in the emergency department with thromboembolic disease, specifically low-risk deep vein thrombosis or pulmonary embolism according to recommendations
- Affiliated with or beneficiary of social protection
- Age 18 years or older
You will not qualify if you...
- Severe obstruction syndrome or thromboembolic disease already under treatment
- Suspicion of heparin-induced thrombocytopenia
- Active hemorrhage or major risk of hemorrhage
- Severe renal failure
- Comorbidities such as cancer
- Inability to organize a consultation or unfavorable medico-social context
- Caval thrombosis
- Hemorrhagic risk diseases or neurosurgery in the last month or other surgery in the last 15 days prior to inclusion
- Contraindications to direct oral anticoagulants including certain drug therapies and anti-phospholipid syndrome
- Living in an area without internet coverage
- No primary care physician
- Inability to understand the study due to language or psychological problems or inability to read or write
- Under legal protection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 6 months to 1 year
Participants use a 4G tablet throughout the study to complete questionnaires, receive patient education, have remote consultations, and evaluate treatment compliance.
Trial Site Locations
Total: 1 location
1
Centre Hospitalier Eure-Seine
Évreux, France, 27000
Actively Recruiting
Research Team
L
Lydia BEN BEKKOU, ARC
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here